iCAD (NASDAQ:ICAD) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of iCAD (NASDAQ:ICAD) from a hold rating to a sell rating in a report released on Wednesday morning.

iCAD Price Performance

ICAD stock opened at $1.64 on Wednesday. iCAD has a 1-year low of $1.18 and a 1-year high of $2.65. The business has a fifty day moving average price of $1.71 and a 200-day moving average price of $1.54. The stock has a market capitalization of $43.53 million, a P/E ratio of -12.62 and a beta of 1.47.

iCAD (NASDAQ:ICAD) last posted its earnings results on Tuesday, August 13th. The technology company reported ($0.07) EPS for the quarter. The firm had revenue of $5.03 million during the quarter. iCAD had a negative return on equity of 15.30% and a negative net margin of 17.81%.

Hedge Funds Weigh In On iCAD

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Eagle Investment Management LLC lifted its stake in iCAD by 3.2% in the 1st quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock worth $1,129,000 after purchasing an additional 22,000 shares in the last quarter. Perritt Capital Management Inc. grew its stake in shares of iCAD by 7.5% during the first quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after purchasing an additional 9,717 shares in the last quarter. Virtu Financial LLC lifted its position in iCAD by 55.6% in the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after acquiring an additional 7,604 shares during the last quarter. Perritt Capital Management Inc lifted its position in iCAD by 14.2% in the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after acquiring an additional 19,917 shares during the last quarter. Finally, Essex LLC purchased a new stake in shares of iCAD in the third quarter valued at about $216,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.